Latest Biotechnology, Pharmaceutical and Healthcare News from OncLive

00:31 EDT 26th September 2018 | BioPortfolio

Here are the most relevant search results for "OncLive" found in our extensive news archives from over 250 global news sources.

More Information about OncLive on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about OncLive for you to read. Along with our medical data and news we also list OncLive Clinical Trials, which are updated daily. BioPortfolio also has a large database of OncLive Companies for you to search.

Showing News Articles 1–25 of 1,000+ from OncLive

Tuesday 25th September 2018

Atezolizumab Prolongs Survival in SCLC

The addition of atezolizumab to standard carboplatin and etoposide in the frontline setting significantly prolonged survival in patients with extensive-stage small cell lung cancer compared with the chemotherapy regimen alone.

Brigatinib Bests Standard of Care to Improve PFS in Advanced NSCLC

Brigatinib reduced the risk of disease progression or death by more than 50% compared to crizotinib in adult patients with ALK-positive, locally advanced or metastatic NSCLC.

Challenges Remain in Prostate Cancer Paradigm

Walter M. Stadler, MD, gives an overview of the current prostate cancer landscape and discussed future directions.

Adding Durvalumab to Chemoradiation Improves OS in Unresectable Stage III NSCLC

Durvalumab induced a clinically meaningful improvement in overall survival compared with placebo in patients with stage III, unresectable non–small cell lung cancer who have not progressed following chemoradiotherapy.

Atezolizumab Regimen Improves PFS in Frontline Nonsquamous NSCLC

The addition of atezolizumab to carboplatin/cisplatin in the first-line setting and to pemetrexed as maintenance therapy significantly improved progression free survival in patients with stage IV nonsquamous NSCLC. 

Neoadjuvant Immunotherapy May Change Standard of Care in Early-Stage NSCLC

Wade T. Iams, MD, and Erin A. Gillaspie, MD, MPH, discuss the impact that immunotherapy has had on the treatment of patients with early-stage non–small cell lung cancer.

Monday 24th September 2018

Repotrectinib Shows Promising Activity in ROS1+ NSCLC

Repotrectinib (TPX-0005) demonstrates a clinically meaningful and durable benefit across multiple doses in patients with ROS1 fusion–positive NSCLC.

Ropotrectinib Shows Promising Activity in ROS1+ NSCLC

Ropotrectinib (TPX-0005) demonstrates a clinically meaningful and durable benefit across multiple doses in patients with ROS1 fusion–positive NSCLC.

Poziotinib Shows Encouraging Activity Among Heavily Pretreated NSCLC Subgroup

Poziotinib demonstrated high antitumor activity in patients with metastatic, heavily pretreated EGFR and HER2 exon 20 mutant non–small cell lung cancer.

FDA Approves Duvelisib for CLL and Follicular Lymphoma

The FDA has approved duvelisib for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma or relapsed/refractory follicular lymphoma.  

FDA Lifts Partial Clinical Hold on Tazemetostat Trials

The FDA has lifted a partial clinical hold on tazemetostat trials, reopening enrollment to clinical studies examining the EZH2 inhibitor in patients with various solid tumors and hematologic malignancies.

Recent Data Support TKI Discontinuation in Patients With CML

Kendra Sweet, MD, sheds light on data regarding treatment discontinuation and how they impact patients with chronic myeloid leukemia.

Great Advances Call for Great Vigilance and Integrity

Maurie Markman, MD, reflects on how technological advances have impacted translational science and clinical medicine.

Sunday 23rd September 2018

Should Fitness Trackers Be Used to Assess Performance Status in Patients With Cancer?

Using wearable activity monitors may eventually supplement standard assessments of performance status and functionality that could inform clinicians, especially because objective evaluation of performance status is difficult to determine.

Saturday 22nd September 2018

Steady Increase in Liver Cancer Death Rates Observed in Adults Aged 25 and Older

A National Center for Health Statistics briefing showed that liver cancer death rates increased significantly for both sexes, with death rates for men 2 to 2.5 times the rate for women from 2000 through 2016.

Friday 21st September 2018

EU Panel Backs Venetoclax/Rituximab Combo in Relapsed/Refractory CLL

The European Medicines Agency’s Committee for Medicinal Products for Human Use is supporting the approval of venetoclax in combination with rituximab for patients with chronic lymphocytic leukemia who have received at least 1 previous therapy.

CHMP Issues Positive Opinion on Pegfilgrastim Biosimilar

The European Medicines Agency's Committee for Medicinal Products for Human Use has recommended approval of filgrastim-sndz, a biosimilar for pegfilgrastim.

EU Panel Grants Positive Opinion to Brigatinib for ALK+ NSCLC

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended full approval of brigatinib (Alunbrig) as a treatment for patients with advanced ALK-positive non–small cell lung cancer who are previously treated with crizotinib (Xalkori).

Wakelee Highlights Latest Treatment Strategies in EGFR+ NSCLC

Heather Wakelee, MD, shares insight on emerging treatment strategies in EGFR–positive non–small cell lung cancer.

Abemaciclib Regimens Approved in Japan for Recurrent HR+/HER2- Breast Cancer

The Japanese Ministry of Health, Labor, and Welfare has approved abemaciclib (Verzenio) for the treatment of patients with HR-positive, HER2-negative unresectable or recurrent breast cancer in combination with fulvestrant (Faslodex) or an aromatase inhibitor. 

Expert Emphasizes Education to Expand Genetic Testing

Jubilee Brown, MD, Brown explains the value of genetic testing for patients predisposed to and diagnosed with ovarian cancer.

Expert Considers Potential New Directions for CAR T-Cell Therapies

Abhinav Deol, MD, discusses the basics of chimeric antigen receptor T-cell therapy, potential new directions for these products, and the possible impact new products might have on the field.

Lead Investigator Discusses Ipatasertib Potential in TNBC

Rebecca Alexandra Dent, MD, MSc, discusses which patients will derive the most benefit with ipatasertib, whether the agent can fill the unmet need for patients with PIK3CA-mutated TNBC, and what she hopes to learn from the results of the ongoing phase III IPATunity130 trial.

Forde Focuses on Future of Early-Stage NSCLC

Patrick M. Forde, MBBCh, discusses the advances in early-stage non–small cell lung cancer, emphasizing neoadjuvant and adjuvant immunotherapy trials in stage I, II, and III disease.

Thursday 20th September 2018

Binimetinib/Encorafenib Combo Approved in Europe for BRAF+ Melanoma

The European Commission has approved the combination of encorafenib (Braftovi) and binimetinib (Mektovi) for the treatment of adult patients with BRAF V600–mutant unresectable or metastatic melanoma.  

Quick Search


News Quicklinks